Invasive mucinous adenocarcinoma of the lung: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

All stages

One path named

Treated as lung adenocarcinoma by stage, with KRAS G12C inhibitors, zenocutuzumab for NRG1 fusions and matched inhibitors for other fusions when found.

The path, in plain words

ZenocutuzumabApprovedBispecific antibody (HER2×HER3)

Zenocutuzumab is the first drug for cancers driven by NRG1 gene fusions, working by blocking HER3 from receiving its growth signal.

Also referenced:Adenocarcinoma of the lungKRAS G12C-mutant non-small-cell lung cancer

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

Questions to ask about this decision

Is Zenocutuzumab the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (all stages), which of the standard options do you recommend and why?
Why: Guideline options include: Treated as lung adenocarcinoma by stage, with KRAS G12C inhibitors, zenocutuzumab for NRG1 fusions and matched inhibitors for other fusions when found.
Am I a candidate for Zenocutuzumab, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care